Cyclin-dependent kinase 4/6 inhibitors (CDKI)-associated venous thromboembolism in patients with hormone receptor (HR)-positive breast cancer

被引：1
|
作者：
Thein, K. Z. [1 ]
Htut, T. Win [2 ]
Myat, Y. M. [1 ]
Han, M. M. [3 ]
Oo, T. H. [4 ]
机构：
[1] Oregon Hlth & Sci Univ, Hematol & Med Oncol Div, Portland, OR USA
[2] Aberdeen Royal Infirm, Dept Hematol, Aberdeen, Scotland
[3] Interfaith Med Ctr, Internal Med, Brooklyn, NY USA
[4] UT MD Anderson Canc Ctr, Sect Benign Hematol, Houston, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1928
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1625P
引用
收藏
页码：S1284 / S1284
页数：1
相关论文
共 50 条
  • [1] Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors
    Gervaso, Lorenzo
    Montero, Alberto J.
    Jia, Xuefei
    Khorana, Alok A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (01) : 162 - 168
  • [2] Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
    Paratore, C.
    Audisio, M.
    Bombaci, S.
    Bungaro, M.
    Dionisio, R.
    Ferrari, G.
    Gaudino, E.
    Grassi, L.
    Hotca, A.
    Loddo, C.
    Manuguerra, G.
    Manzin, E.
    Novello, S.
    Numico, G.
    Persano, I.
    Sculli, C.
    Sperone, P.
    Valsecchi, A. A.
    Zucchini, G.
    Vellani, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S379 - S379
  • [3] Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
    Gervaso, Lorenzo
    Montero, Alberto J.
    Jia, Xuefei
    Khorana, Alok A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
    Rossi, Lorenzo
    McCartney, Amelia
    Risi, Emanuela
    De Santo, Irene
    Migliaccio, Ilenia
    Malorni, Luca
    Biganzoli, Laura
    Di Leo, Angelo
    CLINICAL BREAST CANCER, 2019, 19 (06) : 392 - 398
  • [5] Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Hecht, Keith A.
    Selby, Christopher
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 195 - 203
  • [6] Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
    Spring, Laura M.
    Wander, Seth A.
    Andre, Fabrice
    Moy, Beverly
    Turner, Nicholas C.
    Bardia, Aditya
    LANCET, 2020, 395 (10226): : 817 - 827
  • [7] Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer
    Wander, Seth A.
    Mayer, Erica L.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2866 - +
  • [8] Cyclin-Dependent Kinase 4/6 Inhibition in the Treatment of Hormone Receptor-Positive Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (10) : 555 - 558
  • [9] Incidence and severity of neutropenia in patients treated with cyclin-dependent kinase 4/6 inhibitors (CDKi) for metastatic breast cancer.
    Singh, Anmol
    Giordano, Sharon H.
    Zhang, Ning
    Mac Gregor, Mariana Chavez
    Zhao, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
    Dubianski, Roman
    Jagiello-Gruszfeld, Agnieszka
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
12345